<DOC>
	<DOC>NCT02148120</DOC>
	<brief_summary>The aim of the study is to demonstrate the non-inferiority in terms of acute bronchodilator effect between a single dose of CHF 1535 NEXThaler 200/6 µg and a single dose of CHF 1535 NEXThaler 100/6 µg at two dose levels in partially controlled and uncontrolled asthmatic patients.</brief_summary>
	<brief_title>A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler</brief_title>
	<detailed_description />
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>Patient's written informed consent obtained prior to any studyrelated procedures. Male or female aged between 18 and 65 years inclusive; Evidence for "partially controlled" or "uncontrolled" asthma; Medium daily dose of previous inhaled corticosteroids (ICS) treatment; FEV1 between 60% and 85% of the predicted normal values; A documented positive response to the reversibility test; Nonsmokers or exsmokers; A cooperative attitude and ability to be trained in the proper use of a DPI. Pregnant or lactating women and all women physiologically capable of becoming pregnant not willing to use at least one acceptable method of contraception. Significant seasonal variation in asthma occurring or expected to occur during study participation; History of near fatal asthma, brittle asthma, accident and Emergency treatment or hospitalisation for asthma exacerbation in Intensive Care Unit within 1 year before screening; Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening; Diagnosis of Chronic Obstructive Pulmonary Disease; History of cystic fibrosis, bronchiectasis or alpha1 antitrypsin deficiency; Diagnosis of restrictive lung disease; Patients treated with oral or parenteral corticosteroids in the previous 8 weeks; Intolerance or contraindication to treatment with beta2agonists and/or inhaled corticosteroids; Allergy, sensitivity or intolerance to study drugs or excipients; Patients who received any investigational drug within the last 8 weeks before the screening; Patients taking any of the nonpermitted concomitant medication; Subjects unlikely to comply with the study protocol; Any clinically relevant abnormal value or physical finding at screening; Significant medical history; Abnormal and clinically significant 12lead electrocardiogram; Patients with low compliance of QVAR intake.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>